Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

Acumen Pharmaceuticals unveils new Alzheimer strategy with sabirnetug at Citi conference

Acumen Pharmaceuticals presented its approach to treating Alzheimer’s at Citi’s “Biopharma Back to School Conference,” focusing on the antibody sabirnetug against Aβ oligomers, plans for a subcutaneous formulation, and improved brain targeting in collaboration with JCR Pharmaceuticals. The company emphasized use of biomarkers (including pTau217), AI/ML analyses for data processing, reported positive Phase 1 signals, and highlighted the ongoing ALTITUDE‑AD study for further validation. Acumen sees combination therapies as the future and expects a preclinical EBD candidate in early 2026. » Mais em de.investing.com
Acumen Pharmaceuticals misses Q2 forecast and shares slip in premarket

Acumen Pharmaceuticals reported Q2 2025 EPS of -$0.68, missing the estimate of -$0.51, which led to a 1.41% decline in premarket trading. Higher R&D expenses drove the net loss to $41 million; cash and cash equivalents stood at $166.2 million and are expected to last into early 2027. The company reaffirmed its collaboration with JCR Pharmaceuticals and expects top-line data from the Phase 2 ALPITUDE AD study by the end of 2026. » Mais em de.investing.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2026, JCR PHARM. já distribuiu € 0,0544 em dividendos. A última distribuição ocorreu em junho.

Dados financeiros da empresa

No último trimestre, JCR PHARM. registou receitas de € 52,26 mi e um ganho líquido de -€ 10,28 mi

(EUR)	junho de 2026	YoY
Receitas	52,26 mi	3,37%
Ganho bruto	40,14 mi	10,20%
Ganho líquido	-10,28 mi	219,11%
EBITDA	-8,54 mi	2.294,36%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 360,06 mi
Número de ações	122,02 mi
Máximo/mínimo de 52 semanas	€ 4,67 - € 2,51
Rentabilidade de dividendos	3,82%
Dividendos TTM	€ 0,11
Beta	0,42
PER (PE Ratio)	77,53
PEG (PEG Ratio)	1,19
P/VC (PB Ratio)	1,47
P/V (PS Ratio)	1,53

Perfil da empresa

JCR Pharmaceuticals Co. Ltd. ist ein Spezialpharmaunternehmen, das sich mit der Erforschung, Entwicklung, Herstellung, dem Import und Export sowie dem Verkauf von pharmazeutischen Produkten, regenerativen Arzneimitteln und Drogensubstanzen in Japan beschäftigt. Es bietet verschiedene therapeutische Produkte an, darunter GROWJECT zur Behandlung von Wachstumshormonmangel und Kleinwuchs, IZCARGO zur Behandlung von Mukopolysaccharidose Typ II, Agalsidase Beta BS I.V. Infusion zur Behandlung der Fabry-Krankheit und TEMCELL HS Inj zur Behandlung der akuten Graft-versus-Host-Krankheit. Das Unternehmen entwickelt auch Epoetin Alfa BS und Darbepoetin Alfa BS Injektionen für die Behandlung von renaler Anämie. Darüber hinaus vertreibt das Unternehmen medizinische Geräte und Laborinstrumente. JCR Pharmaceuticals Co., Ltd. wurde 1975 gegründet und hat seinen Hauptsitz in Ashiya, Japan.